Cargando…

Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study

Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab)....

Descripción completa

Detalles Bibliográficos
Autores principales: Vivaldi, Caterina, Fornaro, Lorenzo, Cappelli, Carla, Pecora, Irene, Catanese, Silvia, Salani, Francesca, Cacciato Insilla, Andrea, Kauffmann, Emanuele, Donati, Francescamaria, Pasquini, Giulia, Massa, Valentina, Napoli, Niccolò, Lencioni, Monica, Boraschi, Piero, Campani, Daniela, Boggi, Ugo, Caramella, Davide, Falcone, Alfredo, Vasile, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678367/
https://www.ncbi.nlm.nih.gov/pubmed/31277449
http://dx.doi.org/10.3390/cancers11070939
_version_ 1783441084029861888
author Vivaldi, Caterina
Fornaro, Lorenzo
Cappelli, Carla
Pecora, Irene
Catanese, Silvia
Salani, Francesca
Cacciato Insilla, Andrea
Kauffmann, Emanuele
Donati, Francescamaria
Pasquini, Giulia
Massa, Valentina
Napoli, Niccolò
Lencioni, Monica
Boraschi, Piero
Campani, Daniela
Boggi, Ugo
Caramella, Davide
Falcone, Alfredo
Vasile, Enrico
author_facet Vivaldi, Caterina
Fornaro, Lorenzo
Cappelli, Carla
Pecora, Irene
Catanese, Silvia
Salani, Francesca
Cacciato Insilla, Andrea
Kauffmann, Emanuele
Donati, Francescamaria
Pasquini, Giulia
Massa, Valentina
Napoli, Niccolò
Lencioni, Monica
Boraschi, Piero
Campani, Daniela
Boggi, Ugo
Caramella, Davide
Falcone, Alfredo
Vasile, Enrico
author_sort Vivaldi, Caterina
collection PubMed
description Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.
format Online
Article
Text
id pubmed-6678367
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66783672019-08-19 Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study Vivaldi, Caterina Fornaro, Lorenzo Cappelli, Carla Pecora, Irene Catanese, Silvia Salani, Francesca Cacciato Insilla, Andrea Kauffmann, Emanuele Donati, Francescamaria Pasquini, Giulia Massa, Valentina Napoli, Niccolò Lencioni, Monica Boraschi, Piero Campani, Daniela Boggi, Ugo Caramella, Davide Falcone, Alfredo Vasile, Enrico Cancers (Basel) Article Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy. MDPI 2019-07-04 /pmc/articles/PMC6678367/ /pubmed/31277449 http://dx.doi.org/10.3390/cancers11070939 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vivaldi, Caterina
Fornaro, Lorenzo
Cappelli, Carla
Pecora, Irene
Catanese, Silvia
Salani, Francesca
Cacciato Insilla, Andrea
Kauffmann, Emanuele
Donati, Francescamaria
Pasquini, Giulia
Massa, Valentina
Napoli, Niccolò
Lencioni, Monica
Boraschi, Piero
Campani, Daniela
Boggi, Ugo
Caramella, Davide
Falcone, Alfredo
Vasile, Enrico
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title_full Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title_fullStr Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title_full_unstemmed Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title_short Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
title_sort early tumor shrinkage and depth of response evaluation in metastatic pancreatic cancer treated with first line chemotherapy: an observational retrospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678367/
https://www.ncbi.nlm.nih.gov/pubmed/31277449
http://dx.doi.org/10.3390/cancers11070939
work_keys_str_mv AT vivaldicaterina earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT fornarolorenzo earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT cappellicarla earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT pecorairene earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT catanesesilvia earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT salanifrancesca earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT cacciatoinsillaandrea earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT kauffmannemanuele earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT donatifrancescamaria earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT pasquinigiulia earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT massavalentina earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT napoliniccolo earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT lencionimonica earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT boraschipiero earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT campanidaniela earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT boggiugo earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT caramelladavide earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT falconealfredo earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy
AT vasileenrico earlytumorshrinkageanddepthofresponseevaluationinmetastaticpancreaticcancertreatedwithfirstlinechemotherapyanobservationalretrospectivecohortstudy